| INTRODUC TI ON
Affecting >85 million Americans, hypertension is a major risk factor for heart disease, stroke, renal disease, and poor cardiovascular (CV) outcomes. [1] [2] [3] [4] In 2014, approximately 73 000 deaths in the United
States were attributed to hypertension, an increase of 34.1% since 2004. 5 While many efficacious options for pharmacologically lowering blood pressure (BP) are available-including angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptors blockers (ARBs), calcium channel blockers (CCBs), diuretics, aldosterone antagonists, and β-blockers 6 -hypertension remains uncontrolled in nearly 50% of hypertensive adults, 7 and the prevalence of resistant hypertension is rising. 8 β-blockers are a diverse class of drugs once considered a core treatment option for achieving BP control; however, current US practice guidelines no longer recommend β-blockers as first-line therapy. 6 The current recommendations are based on long-term outcome studies and meta-analyses in which treatment with nonvasodilatory β-blockers was associated with undesirable CV and stroke outcomes. [9] [10] [11] [12] [13] An acknowledged limitation of those studies was that the β-blockers investigated may not fully represent this heterogeneous drug class. 12, 14 Newer vasodilatory β-blockers, namely carvedilol and nebivolol, have distinct mechanisms of action from previous generations of β-blockers and from each other. 15, 16 Unlike atenolol and metoprolol, which are non-vasodilatory β 1 -selective adrenergic receptor antagonists carvedilol is a nonselective β-adrenergic antagonist with vasodilation occurring via α 1 -adrenergic antagonism. 14, 17 Nebivolol is also vasodilatory, but is a highly β 1 -selective antagonist with β 3 -agonistic and nitric oxide-mediated vasodilatory properties. 18, 19 Such distinct pact on energy" and "arterial vasodilation" as more important than PCPs (P < 0.05/<0.01, respectively). Awareness of vasodilation was greater for carvedilol (52%) than nebivolol (31%). Association between β-blockers and clinical variables included nebivolol with β 1 -selectivity, nebivolol and carvedilol with vasodilation and efficacy in older patients and African Americans, metoprolol with heart rate reduction, and atenolol and metoprolol with weight gain and hyperglycemia. Physicians preferred prescribing β-blockers with lower risk of incident diabetes. Clinical practice guidelines influenced physician prescribing more than formularies or performance metrics. This survey captures physicians' perceptions/use of various β-blockers and clinically relevant knowledge gaps.
mechanisms of action may contribute to improved CV event risk and may reduce side effects over non-vasodilatory β-blockers, with potential implications for adherence and persistence. [20] [21] [22] [23] Indeed, a large retrospective cohort study examining CV event risk leading to hospitalization in hypertensive patients receiving one of three β 1 -selective blockers (nebivolol, metoprolol, or atenolol)
as monotherapy revealed that nebivolol treatment was associated with lower risk of CV-related hospitalization than either atenolol or metoprolol. 24 Hypertension clinical practice guidelines now recommend a target systolic blood pressure (SBP)/diastolic blood pressure (DBP) <130/80 mm Hg for adults with confirmed cardiovascular disease (CVD), 10-year atherosclerotic CVD event risk ≥10%, or for patients with diabetes mellitus, chronic kidney disease, or who are >65 years old. 6 In order to achieve target blood pressure, most patients will require ≥2 antihypertensives. 25 By combining treatments with different but complementary mechanisms of action (eg, ACEIs or β-blockers with diuretics and CCBs), additive effects on BP reduction may be achieved, allowing for lower dosages of both drugs. 25, 26 Given the current hypertension guidelines and the need for multiple antihypertensives to achieve BP control, β-blockers will continue to play an important role as add-on therapy in hypertension management.
To assess the importance of factors that may influence physicians when prescribing antihypertensives, particularly β-blockers, a 20-minute quantitative online survey was conducted to identify physician perceptions, knowledge, and prescribing of currently available treatments among cardiologists and primary care physicians (PCPs).
| ME THODS
The 20-minute web-based survey was designed and conducted to β-blocker prescriptions in the last 3 months. Informed consent was obtained prior to initiation of the survey, which was conducted according to Market Research Society guidelines. 27 The identities of the participants were kept confidential and were not disclosed to the sponsor company. Differences between PCPs and cardiologists were examined by t tests to determine significance between means and by z tests to determine significance between percentages. and PCPs (78%) were from private offices or clinics. In the 3 months prior to the survey, cardiologists and PCPs self-reported seeing an average (±standard deviation) of 499 ± 226 and 399 ± 195 hypertensive patients, respectively, with 29% and 20% being new patients.
| RE SULTS

| Participating physicians
| Antihypertensive use
Compared with PCPs, a significantly higher proportion of cardiologists' caseloads were prescribed β-blockers (cardiologists, 46%;
PCPs, 28%; P < 0.01) and aldosterone antagonists (12% vs 7%, P < 0.01) for hypertension. Though the treatment of choice among all physicians for first-line therapy was an ACEI, a significantly greater proportion of patients were prescribed β-blockers as a firstline therapy by cardiologists than by PCPs (30% vs 17%, P < 0.01; Figure 1A ). For second-line therapy, a similar proportion of patients were prescribed ACEIs (25%), diuretics (26%), ARBs (23%), β-blockers (25%), or CCBs (23%), while only 5% received aldosterone antagonists; differences were not significant between cardiologists and PCPs (data not shown).
| β-blocker use
In the previous 3 months, metoprolol was the most commonly prescribed β-blocker (cardiologists, 40%; PCPs, 42%), followed by carvedilol (33% vs 26%, P < 0.05), atenolol (13% vs 18%), nebivolol (8% vs 7%), bisoprolol (5% vs 8%, P < 0.05), or other β-blockers (2% vs 1%). For both cardiologists and PCPs, nearly three-quarters of patients taking β-blockers were either prediabetic and/or obese (74%, each). A similar percentage of diabetic patients were treated with β-blockers by cardiologists (23%) and PCPs (25%).
Fatigue was the leading reason for not prescribing β-blockers, ranking in the top three reasons most of the time for both cardiologists (78%) and PCPs (82%; Figure 2 ). Most physicians did not consider formulary/payer considerations, a reason for not prescribing β-blockers.
| β-blocker attributes
The key drug features considered by physicians when choosing a particular β-blocker included the ability to reduce heart rate, efficacy in patients aged >60 years, side effects other than fatigue, β 1 -selectivity, impact on fatigue/energy, and impact on arterial vasodilation (Table 1) . Among physicians surveyed, 52% of physicians (68% cardiologists, 43% PCPs) closely associated carvedilol with vasodilation. In contrast, only 31% of physicians (36% cardiologists, 29% PCPs) associated nebivolol with vasodilation.
More PCPs than cardiologists associated all queried β-blockers with vasodilation (17% vs 5%, P < 0.05). A significantly greater number of cardiologists than PCPs were aware of the specific mechanisms by which either carvedilol or nebivolol achieve vasodilation (carvedilol: 86% cardiologists, 58% PCPs, P < 0.01; nebivolol: 51% vs 30%, P < 0.01).
When asked about features physicians associated with a particular β-blocker (0 = not at all associated; 10 = very closely associated; mean scores, has primary vasodilating properties. 28 Metoprolol and atenolol were strongly associated with reducing heart rate (metoprolol, 7.6; atenolol, 7.5). Nebivolol and carvedilol were least associated with fatigue (Table 2) .
Physicians reported varied associations between specific β-blockers and changes in weight or glucose levels ( Figure 3A,B) .
Approximately one-third of cardiologists and PCPs were unaware that β-blockers are associated with weight gain (34% vs 39%), 29 while 42% of surveyed physicians were unaware that any β-blockers are associated with a clinically relevant increase in glucose. 30 Atenolol and metoprolol were most associated with weight gain and clinically relevant changes in glucose, while nebivolol was least associated with either outcome. Only 10% of cardiologists and 2% of PCPs associated carvedilol with weight gain (P < 0.05).
| Importance of β-blocker attributes
When physicians were asked about the importance of particular drug attributes when choosing treatments, cardiologists rated "arterial vasodilation" and "impact on fatigue/energy" as more important features for β-blocker selection than PCPs (Table 1) .
On a scale of 0 to 10 (0 = no value; 10 = very valuable), cardi- 
β-blockers
Nebivolol
Carvedilol Atenolol Metoprolol
Reduction in heart rate 6.2 ± 2.3 6.9 ± 2.1 7.5 ± 1.9 7.6 ± 1.9
Efficacy in patients aged >60 y The four β-blockers queried in this survey question were included based on the expectation of frequency of use and clinical utility. *P < 0.05. **P < 0.01 in favor of cardiologists vs PCPs. † P < 0.05. † † P < 0.01 in favor of PCPs vs cardiologists.
TA B L E 2 Association of Features with
β-blockers Used a (All Physicians)
| Special populations
An analysis of the first-line therapy used in special populations revealed that African American patients were frequently treated with diuretics (35%) and CCBs (26%; Figure 1B ), diabetic patients were frequently prescribed ACEI (60%) or ARBs (26%; Figure 1C ), and cardiologists prescribed β-blockers to greater percentages of African Americans (21% vs 17%) and diabetic patients (16% vs 10%, P < 0.05) than PCPs ( Figure 1B,C) . 
| Educational preferences
Continuing medical education (CME) was a major source of education for physicians, both in terms of frequency used and preference for material (ranked in the top 3, Figure S1 ). Publications and sales representatives were also among the most frequently utilized resources, and publications and medical conferences were other top preferred sources of educational material (ranked in the top 3, Figure S1 ). However, cardiologists used publications more frequently (ranked first, 46% vs 30%, P < 0.05) and indicated a greater preference for publications as a method for obtaining hypertension information than PCPs (ranked first, 37% vs 26%). On a scale of 0 to 10 (0 = not at all impactful; 10 = very impactful), clinical practice guidelines (mean score = 8.0) influenced prescribing behaviors more than either formulary (mean score = 6.7) or performance metrics (mean score = 6.1), with no differences between cardiologists and PCPs.
| Unmet needs
Both cardiologists and PCPs ranked "better efficacy" as the highest unmet need in hypertension (cardiologists, 47%; PCPs, 39%), followed by "resistant hypertension" (22% vs 36%), "fewer adverse events" (25% vs 18%), and "new fixed-dose combinations" (5% vs 7%). These top unmet needs did not significantly differ between cardiologists and PCPs.
| D ISCUSS I ON
While the percentage of patients achieving BP control with treatment over the last 20 years has increased, hypertension remains a major public health concern and the aim of national programming efforts. 7, 31 Consistent with these goals, surveyed physicians identified improvement in efficacy, better BP control with fewer side effects, and treatment of resistant hypertension as major areas of unmet needs. Additionally, physicians reported using β-blockers primarily as a second-line or later therapy for hypertension consistent with current hypertension management guidelines, 6 which recommend diuretics, CCBs, ACEIs, or ARBs as first-line therapy, and β-blockers as add-on medication absent compelling indications.
The goal of this study was to identify physician perceptions of β-blockers and educational opportunities when perceptions did not align with known pharmacology or clinical evidence. Several such areas were identified in this study. First, physicians cited fatigue as the main reason for not using β-blockers, a common reason for study discontinuation in clinical trials of early-generation β-blockers such as propranolol, atenolol, or timolol. 6, 21 However, recent clinical evidence suggests that fatigue and other β-blocker side effects are drug-specific rather than a class-wide effect. 12, 14, 32 Second, physicians were split on their awareness of β-blockers' impact on weight gain: Surveyed physicians either associated all queried β-blockers with weight gain, were unaware that β-blockers affect weight gain, or associated only certain β-blockers-atenolol and metoprolol in particular-with these effects. Clinical data support the latter. 29, 33, 34 20, 44 Because many of the patients treated by surveyed physicians were prediabetic, diabetic, or obese, and given the relative metabolic benefit of vasodilatory versus non-vasodilatory β-blockers, these survey findings suggest a substantial opportunity for educating physicians on β-blockers that do not affect weight or blood glucose levels. 43 There were several instances in which cardiologists diverged significantly from PCPs in their perception or use of β-blockers. For example, cardiologists prescribed β-blockers to a greater proportion of patients, were more likely to use β-blockers as first-line treatment for hypertension, and prescribed different types of β-blockers than PCPs.
One likely explanation for these differences is that cardiologists saw more patients with complicated hypertension who presented with additional conditions including systolic heart failure, previous myocardial infarction, or ischemic heart disease, for which β-blockers are indicated and effective. 6, 45, 46 On β-blocker features, PCPs more highly associated atenolol and metoprolol (incorrectly) with vasodilation; as noted above, only carvedilol and nebivolol are vasodilatory. Knowledge of this drug property has important clinical implications: BP lowering by non-vasodilatory β-blockers occurs primarily via reduced cardiac output, whereas vasodilatory β-blockers primarily decrease peripheral vascular resistance. 47 Additionally, while surveyed physicians highly associated nebiv- The findings from this survey indicate that long-term studies on the differential and possibly beneficial effects of newer generation β-blockers on various clinical outcomes are warranted, particularly in prediabetic, obese, and other special populations. In particular, studies aimed at clarifying the effects of carvedilol and nebivolol would be valuable given that recent meta-analyses suggested that BP lowering by combined β/α-receptor blockers (ie, carvedilol) was less effective than by β 1 -selective blockers (ie, nebivolol). 49, 50 As the most frequently used and preferred source of education by physicians in this study, CME modules and peer-reviewed publications may provide greater benefit than other initiatives for accessible and consistent educational efforts.
The results of this survey should be considered with the follow- 
| CON CLUS IONS
This survey highlights several educational gaps in and between
PCPs and cardiologists, on their knowledge and prescribing of β-blockers for hypertension treatment. Future educational and research efforts should highlight how differences between β-blockers impact side effects, hypertension control, and patient outcomes and how this information is most effectively conveyed to prescribing physicians.
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